Nadolol
Corgard, Corzide (nadolol) is a small molecule pharmaceutical. Nadolol was first approved as Corgard on 1982-01-01. It is used to treat angina pectoris, heart failure, hypertension, and myocardial infarction in the USA. The pharmaceutical is active against beta-2 adrenergic receptor and beta-1 adrenergic receptor. In addition, it is known to target beta-3 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Nadolol (discontinued: Corgard, Nadolol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bendroflumethiazide
+
Nadolol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORZIDE | King Pharmaceuticals | N-018647 DISCN | 1983-05-25 | 2 products, RLD |
Hide discontinued
Nadolol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORGARD | US WorldMeds | N-018063 DISCN | 1982-01-01 | 5 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nadolol | ANDA | 2024-10-09 |
| nadolol and bendroflumethiazide | ANDA | 2016-04-15 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | 1 | 3 | 2 | 7 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | 1 | 3 | — | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 4 | — | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 4 | — | 4 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | 2 | — | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 3 | — | 3 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 3 | — | 3 |
| Fibrosis | D005355 | — | — | — | — | — | 3 | — | 3 |
| Gastrointestinal hemorrhage | D006471 | HP_0002239 | K92.2 | — | — | 1 | 1 | — | 2 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | 1 | 1 | — | 2 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemangioma | D006391 | — | D18.0 | — | 1 | 1 | — | — | 2 |
| Port-wine stain | D019339 | — | Q82.5 | — | 1 | 1 | — | — | 2 |
| Capillary hemangioma | D018324 | — | Q82.5 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 2 | — | — | — | 2 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Chest pain | D002637 | HP_0100749 | R07.9 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | — | — | — | — | 1 |
| Cell- and tissue-based therapy | D064987 | — | — | 1 | — | — | — | — | 1 |
| Adoptive immunotherapy | D016219 | — | — | 1 | — | — | — | — | 1 |
| Lymphocyte transfusion | D017710 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
| Ventricular tachycardia | D017180 | — | I47.2 | — | — | — | — | 1 | 1 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nadolol |
| INN | nadolol |
| Description | Nadolol, sold under the brand name Corgard among others, is a medication used to treat high blood pressure, heart pain, atrial fibrillation, and some inherited arrhythmic syndromes. It has also been used to prevent migraine headaches and complications of cirrhosis. It is taken orally.
|
| Classification | Small molecule |
| Drug class | analgesics (mixed opiate receptor agonists/antagonists); beta-blockers (propranolol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2 |
Identifiers
| PDB | — |
| CAS-ID | 42200-33-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL649 |
| ChEBI ID | — |
| PubChem CID | 39147 |
| DrugBank | DB01203 |
| UNII ID | FEN504330V (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nadolol
+
Bendroflumethiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Nadolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,215 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use